Clinical trials: Immediate Hypersensitivity
Type I Hypersensitivity
Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of the modified ragweed pollen in Ragweed MATA MPL (modified pollen allergen tyrosine adsorbate + Monophosphoryl Lipid A) by skin prick testing.
- Trial name
- NCT00116285
- Testing
- Ragweed MATA MPL
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
Safety and tolerability of different dose combinations of MPL and grass pollen allergen and to identify the highest combinations of MPL and grass pollen allergen which is safe.
- Trial name
- NCT00241410
- Testing
- OralvacB2MPL
- Where
- Germany
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
Ragweed MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to ragweed pollen (hay fever).
- Trial name
- NCT00325338
- Testing
- Ragweed MATAMPL
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Grass MATA MPL
Grass MATA MPL has been developed by Allergy Therapeutics (UK) Ltd. to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens causing rhinitis and/or…
- Trial name
- NCT00414141
- Testing
- Grass MATA MPL
- Where
- 94 sites in United States, Austria and 2 more
- Volunteers
- 1,028 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Efficacy and Safety/Tolerability of Ragweed MATA MPL
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis…
- Trial name
- NCT00423787
- Testing
- Ragweed MATA MPL
- Where
- 76 sites in United States, Canada
- Volunteers
- 993 people
- Sponsor
- Allergy Therapeutics
Type I Hypersensitivity
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00104390
- Testing
- Grass MATA MPL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Allergy Therapeutics